Accessibility Menu
Brainstorm Cell Therapeutics logo

Brainstorm Cell Therapeutics(OTC) BCLI

Market Cap$8.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-84%
5 YearN/A
1 Year+31%
1 Month-35%
$0.83
+3.75%
+0.03Today
Brainstorm Cell Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.802026-08-06
Brainstorm Cell Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.85%USD 0.922026-07-30
1 month-35.13%USD 1.232026-07-07
3 month+15.18%USD 0.692026-05-08
Year to date+44.67%USD 0.552025-12-31
1 year+31.15%USD 0.612025-08-06
Since inception-84.2%USD 5.062003-05-28

Brainstorm Cell Therapeutics Financials at a Glance

Market Cap

$8.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.57M

EPS (TTM)

-$0.94

P/E Ratio

-0.85

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.83

Volume

1,268

Open

$0.83

Previous Close

$0.80

Daily Range

$0.80 - $0.83

52-Week Range

$0.46 - $1.69

Estimated Earnings Date

Aug 17, 2026

BCLI News

Foolcom-Featured.png

Brainstorm Posts 43% EPS Gain in Q2

Motley Fool Markets TeamAug 14, 2025
Gloved and masked medical researchers using microscopes in their work

Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today

Eric VolkmanFeb 4, 2021
GettyImages-459898185

Why BrainStorm Cell Therapeutics Stock Imploded Today

Prosper Junior BakinyNov 17, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Brainstorm Cell Therapeutics

Brainstorm develops cell therapies for people with neurodegenerative diseases. Its main product aims to help patients with conditions like ALS and multiple sclerosis. The company uses patients’ own cells to try to improve nerve function.

Products and Services

  • NurOwn cell therapy: Uses a patient’s own bone marrow cells to target ALS and multiple sclerosis (0% of revenue; no commercial sales).
  • Exosome-based therapies: Researching cell-derived particles for possible use in brain and lung diseases (0% of revenue).
  • Expanded Access Program: Provided NurOwn to select ALS patients after clinical trials (0% of revenue).
  • Manufacturing partnerships: Works with Catalent and Minaris for production and supply chain support.

Growth and Expansion

  • Signed manufacturing partnership with Catalent in 2021 to scale up NurOwn production.
  • Entered a letter of intent with Minaris in 2025 for future manufacturing support.
  • Expanded into exosome-based research by 2025, broadening its pipeline beyond cell therapy.
  • Operates in the US and Israel, with R&D centered in Israel since 2004.
  • Submitted and withdrew a regulatory application for NurOwn in ALS in late 2023; planning a new Phase 3b clinical trial as of 2024.

What Makes Brainstorm Stand Out

Brainstorm’s therapies use each patient’s own cells, reducing immune rejection risk. Its proprietary process allows multiple treatments from one bone marrow sample. The company holds about 30 patents, including for exosome technology.

Five Things You Need to Know

  • No revenue reported from 2023 to 2025; all activities are pre-commercial.
  • Net loss was $-2M in QQ3 2025, improving 32.8% from QQ3 2024.
  • Cash used in operations was $-1M in QQ3 2025, up 66.6% from QQ3 2024.
  • Delisted from Nasdaq in July 2025; now trades on OTCQB Venture Market.
  • Auditors express doubt about ability to continue without new funding as of December 2025.

Bottom Line

Brainstorm focuses on cell therapies for neurodegenerative diseases but has no commercial sales. The company faces ongoing financial and regulatory challenges as it seeks to advance its pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

19

CEO

Chaim Lebovits

Website

www.brainstorm-cell.com

Headquarters

New York City, NY 10019, US

BCLI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

109.21%

Return on Capital

N/A

Return on Assets

-1676.01%

Earnings Yield

-1.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.03M

Volume

1.27K

Avg. Volume

19.70K

Financials (TTM)

Gross Profit

-$85.00K

Operating Income

-$8.91M

EBITDA

-$8.73M

Operating Cash Flow

-$6.66M

Capital Expenditure

$0.00

Free Cash Flow

-$6.66M

Cash & ST Invst.

$15.00K

Total Debt

$1.49M

Brainstorm Cell Therapeutics Performance Analysis

Brainstorm Cell Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Brainstorm Cell Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Brainstorm Cell Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -9.97-1.6%
20232023-12-31USD -5.99-40.0%
20242024-12-31USD -2.31-61.3%
20252025-12-31USD -1.11-52.0%
Brainstorm Cell Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3024.4%
Q32025-09-3044.1%
Q42025-12-31-15.8%
Q12026-03-3113.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$37.00K

+28.8%

Gross Margin

0.00%

N/A

Market Cap

$8.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$441.39K

N/A

Employees

20

N/A

Net Income

-$2.13M

+25.7%

EBITDA

-$2.01M

+33.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$15.00K

-99.1%

Total Debt

$1.49M

-15.9%

Accounts Receivable

$122.00K

+82.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.49M

-9.4%

Return on Assets

-16.76%

N/A

Return on Invested Capital

79.60%

N/A

Free Cash Flow

-$1.32M

+19.1%

Operating Cash Flow

-$1.32M

+19.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCDABioCardia, Inc.
$0.94-0.98%
ADXNAddex Therapeutics Ltd
$5.74-1.12%
ADILAdial Pharmaceuticals, Inc.
$4.73-1.46%
CDIOCardio Diagnostics Holdings, Inc.
$1.75+5.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$126.29+0.10%
TTDThe Trade Desk
$14.29-0.19%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.65+0.02%
PLTRPalantir Technologies
$169.79+0.09%

Questions About BCLI

What is the current price of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics is trading at $0.83 per share.

What is the 52-week range for Brainstorm Cell Therapeutics?

Over the past 52 weeks, Brainstorm Cell Therapeutics has traded between $0.46 and $1.69.

How much debt does Brainstorm Cell Therapeutics have?

As of the most recent reporting period, Brainstorm Cell Therapeutics reported total debt of $1.49M.

How much cash does Brainstorm Cell Therapeutics have on hand?

Brainstorm Cell Therapeutics reported $15.00K in cash and cash equivalents in its most recent financial results.

What is Brainstorm Cell Therapeutics’s dividend yield?

Brainstorm Cell Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services